Compass Therapeutics Sets Date to Unveil Key Secondary Endpoints from Phase 2/3 Cancer Study
CMPX has more than doubled off its 52-week low of $1.665 on elevated volume (1.9× avg).
Summary
Compass Therapeutics announced it will host a webcast on April 27, 2026, to present topline secondary endpoint data from its Phase 2/3 COMPANION-002 clinical study of tovecimig in patients with advanced biliary tract cancer. This announcement provides a specific date for a significant data release, following the company's general mention of positive clinical trial advancements in its recent 10-K. For a clinical-stage biopharmaceutical company, the outcome of Phase 2/3 clinical trials is a critical value driver, and while these are secondary endpoints, they can still provide important insights into the drug's profile. Traders will be closely watching the webcast for the actual data, which will likely determine the stock's immediate reaction and future prospects for this program.
At the time of this announcement, CMPX was trading at $5.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $904M. The 52-week trading range was $1.67 to $6.88. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.